Equities researchers at UBS Group started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) in a research note issued to investors on Friday, Benzinga reports. The brokerage set a “buy” rating and a $55.00 price target on the stock. Separately, Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research […]

Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Wednesday, Zacks reports. Cyclerion Therapeutics Trading Down 100.0% About Cyclerion Therapeutics (Get Free Report) Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the […]